IMRA

IMARA Inc. [IMRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMRA Stock Summary

Top 10 Correlated ETFs

IMRA

Top 10 Correlated Stocks

IMRA

In the News

IMRA Financial details

Company Rating
-
Market Cap
165.8M
Income
-5.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
41
Optionable
No
Shortable
Yes
Earnings
04 May 2023
P/E
7087.8
Forward P/E
-
PEG
-467.44
P/S
-
P/B
401.53
P/C
-
P/FCF
-4.2
Quick Ratio
26.7
Current Ratio
27.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.88
EPS next Y
-
EPS next Q
-
EPS this Y
-102.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
25%
-
-
-
-
SMA20
-9.57%
SMA50
0.08%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
5%
ROE
13%
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.9739-6.32
52W High
-
52W Low
-
RSI
39.79
Rel Volume
0.32
Avg Volume
116.26K
Volume
37.04K
Perf Week
-3.79%
Perf Month
-21.49%
Perf Quarter
-
Perf Half Y
2.65%
-
-
-
-
Beta
1.08129
-
-
Volatility
0.94%, 4.65%
Prev Close
-5.42%
Price
46.41
Change
-4.96%

Something similar

Top by Market Cap
ABEA.DE
LLY
CMC.DE
MSF.DE
BRYN.DE
Top Correlated ETFs
BABX
Top Correlated Stocks
DECK
MNSO
BURL
0M18.L
FFNTF
Similar Market Cap
AVES.DE
ROL.SW
AXS.L
RXL
XRES.L

Company Profile

Healthcare Biotechnology
  • Volume Average 116.26K
  • Market Capitalization 165.8M
  • Employee 41
  • CEO Dr. Rahul D. Ballal Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2020-03-12
  • Website https://imaratx.com

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.